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Abstract
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most 
frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly 
they are a major initiator of acute exacerbations of chronic airway diseases. Infections can be life 
threatening in the latter context however RV -induced common colds have an associated economic 
cost from loss of productivity due to absence from work or school. There are no appropriate 
antiviral therapies available and vaccine strategies have failed because of the large number of viral 
serotypes and the lack of cross-serotype protection generated. Here, approaches past and present 
for development of a vaccine to these widespread human pathogens are highlighted.
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Background
Rhinoviruses (RVs) are a species of human pathogens belonging to the genus enterovirus of 
the picornaviridae family of viruses [1]. RVs are very small viruses about 30nm in diameter 
that contain a positive sense ssRNA genome of approximately 7500bp that is surrounded by 
a protein capsid which is composed of 60 copies of four protein subunits that assemble an 
icosahedron. These structural proteins consist of the externally facing virus protein 1 (VP1), 
VP2 and VP3 and internal VP4 which lies at the interface of the capsid and RNA genome 
[2]. RVs infect and cause disease in all humans but most significantly in those individuals 
with underlying lung diseases such as asthma or chronic obstructive pulmonary disease, 
where they are a major precipitant of acute exacerbations [3]. The success of RV’s as human 
pathogens is due not only to their speed of infection and onward transmission but also to 
their ability to adapt and change, resulting in the existence of numerous antigenically 
distinct serotypes. The original definition and numbering of serotypes from 1 to 100 was 
based on antibody neutralisation properties with polyclonal antisera where little or no cross-
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serotype neutralization was observed [4]. Antibodies are directed against the outer surface of 
the RV capsid most commonly to exposed areas of VP1, VP2 and VP3 [5, 6]. Regions of the 
capsid sequences display a high degree of heterogeneity amongst serotypes where there are 
areas with less than 70% homology within the RV polyproteins (Figure 1) [7]. These result 
in variable surface-exposed immunodominant epitopes that can dictate serotypespecific 
immune responses. Based on RNA genome sequence analyses, RV’s have now been divided 
into three groups known as RV types A, B and C [8] and may be further classified by entry 
receptor usage. Approximately 90% of characterized RV strains (major group) use 
intercellular adhesion molecule-1 (ICAM-1) as receptors to enter host epithelial cells [9] 
whereas the minor group exploits members of the low-density lipoprotein (LDL) receptor 
family [10]. The entry receptor for group C RV’s has yet to be identified due to propagation 
difficulties in vitro [11] making it difficult to compare serological responses and to therefore 
pinpoint the exact number of RV serotypes. However, based upon the newer molecular 
methods to genetically assign RV groupings there is likely to be significantly more than the 
fully characterized 100 distinct serotypes [12]. When the numbers of distinct RV infections 
are characterized molecularly by sequencing the VP4/VP2 region, it has been estimated that 
47% of infections are due to group A, 12% to group B and 39% to group C [13]. These 
numbers suggest that upwards of 160 RV serotypes exist and are in circulation. The fact that 
adults experience on average of 2-5 infections and children up to 10 infections per year [14], 
when coupled with the lack of cross protective immunity between serotypes [15], ensures 
that humans can expect a lifetime of RV infections. A broadly cross protective vaccine could 
alleviate many of these infections and the associated health and economic issues, 
particularly in those with underlying chronic airways diseases.
Early attempts at RV vaccines
During the late 1960s and early 1970s clinical trials were performed to investigate a 
common cold vaccine, largely through administration of a formalin inactivated single RV 
serotype (RV13) [16, 17, 18, 19, 20, 21]. This approach was found to provide only minimal 
protective effects and was abandoned in favour of testing of inactivated multivalent vaccines 
spanning 10 serotypes [22]. Although these vaccines attempted to address the issue of weak 
cross-serotype protection induced by monovalent vaccination, they also lost popularity when 
surprisingly they failed to induce significant cross protection amongst RV serotypes. Table 1 
summarises these studies that have been performed in humans using inactivated RV 
preparations as vaccines. We now suspect that inactivation of RV for vaccine studies is 
unfavourable for the generation of significant cell mediated immune responses and that the 
antibody responses alone that are often generated in such situations are insufficient for broad 
protection [23]. Formalin treatment was the most common method for RV inactivation [16, 
17, 18, 19, 20, 21] although alternative methods such as heat treatment (pasteurisation), low 
pH and UV treatment are also effective [24, 25, 26]. These methods, whilst largely safe for 
human application, are likely to destroy many epitopes required for optimal immune 
responses and therefore can impact negatively on vaccine efficacy by reducing preparation 
immunogenicity [27]. In addition, another potential reason as to why these prior studies 
displayed limited success is that there was no evidence indicating that an adjuvant was used 
to amplify immune responses. The use of adjuvants would most likely have improved 
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vaccine efficacy significantly [28] however, at that time, Alum was the only approved 
adjuvant for use in humans whilst there are now several others available [29].
Following the human trials, experimental studies in immunised animals (rabbits and mice) 
began to determine some properties of antibody cross reactivity [30, 31, 32] briefly 
encouraging renewed hope for a RV vaccine as cross-serotype neutralising antibodies were 
convincingly demonstrated (Table 2). Despite these positive steps, RV vaccine research 
studies in the scientific literature then virtually disappeared for over 20 years before further 
studies in immunised animals with recombinant RV capsid protein subunits and synthetic 
peptides again proposed possibilities for cross-serotype protective antibodies generation. 
Here, short conserved regions at the N-terminus of the capsid protein VP4 were identified 
that elicit cross-serotype protective antibodies [33] and others found that the entire VP1 
polypeptide had similar effects [34]. Despite these encouraging studies and the application 
of modern molecular analyses, the formal demonstration of protective vaccine responses to 
RV’s in in vivo settings remained elusive largely because of the absence of a small animal in 
vivo model of RV infections.
Recent approaches using mouse models of human RV infection
The advent of a mouse model of human RV infection [26] has permitted new approaches for 
RV vaccine development where specific RV challenge following immunisation can be 
addressed. Previously, infection of mouse cells and indeed live mice with human RV’s was 
not thought possible due to significant sequence differences between the major group entry 
receptor human ICAM-1 and the mouse counterpart [35]. Furthermore, there was a lack of 
sustained intracellular viral replication in mouse cells despite minor group RV having the 
ability to enter via the mouse LDL receptor [36]. Mice transgenic for human ICAM-1, and 
improved methods for generating high titre RV inoculum, have now allowed the intranasal 
infection of mice with RV’s [26]. Here, RV was shown to replicate and cause acute lung 
inflammation as well as activating innate immune responses and initiating adaptive immune 
responses. Immunisation and challenge strategies have subsequently been investigated in 
this model system [7, 23], providing a basis for evaluating the immunological correlates of 
protection to RV’s in vivo. Hyper-immunisation of mice with inactivated RV1B, followed 
by homologous intranasal challenge, generated strong cross-serotype neutralising humoral 
immune responses which were directed at the capsid protein VP1 [23]. Although these 
antibody responses were neutralising in vitro, similar to prior experimentation in humans, 
very little protective effect was observed in vivo further confirming that the use of 
inactivated RV preparations as immunogens does not provide the appropriate 
immunological stimulation that can result in broad RV protection.
Thus an alternate approach was initiated that focussed on the induction of broadly reactive T 
cell immunity. Here, a conserved region (VP0) of the RV polyprotein amongst type A and 
type B strains was identified (Figure 1), the recombinant protein was produced in E. coli and 
used as an immunogen in mice [7]. In this study, recombinant VP0 derived from RV16 was 
immunogenic in vivo, inducing immunogen and RV-specific antibodies and cross-serotypic 
systemic cellular immune responses. Furthermore, the use of a Th1-promoting adjuvant in 
combination with VP0 induced cross-serotype cellular T lymphocytes producing the Th1 
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cytokine IFNγ and improved Th1-associated RV-specific antibody responses. It was also 
shown that immunised mice challenged with heterologous RV strains displayed enhanced 
cross-reactive cellular, increased memory CD4 T cell numbers and stronger humoral 
immune responses suggesting broad cross-serotype reactivity was obtained with this 
strategy. Most importantly, VP0 immunisation followed by live RV challenge improved the 
generation of neutralising antibodies to a variety of RV serotypes and also caused more 
rapid virus clearance in vivo. VP0 therefore represents a useful candidate for a subunit RV 
vaccine and may function by generating significant cross-reactive Th1 cells that upon 
heterologous RV challenge quickly stimulates additional protective immune responses [7]. 
Further experimentation in this model system of RV infection and translation to humans 
awaits.
Very recently it has been shown that cotton rats are permissive for RV16 infection and 
display characteristics similar to the mouse RV infection model [37]. Interestingly, in this 
model, prior immunisation with inactivated RV via the intramuscular route but not by the 
intranasal route produced significant neutralising antibody responses and reduced the viral 
load in the lungs upon homotypic challenge, confirming findings in the mouse model [7, 
23]. In further experiments both prophylactic antibody administration and maternal 
immunity transfer to neonates were both protective although heterotypic responses were not 
evaluated [37]. The use of this model system in addition to the mouse model will 
complement human studies and hopefully aid in the identification and development of RV 
vaccines.
Public health challenges of RV vaccine delivery to humans
There is a large unmet medical need resulting from RV infections that would be corrected by 
a safe and effective vaccine. The major target population of an RV vaccine would be those 
suffering from chronic lung diseases such as asthma and chronic obstructive pulmonary 
disease where infections with RV are a major precipitant of life threatening acute 
exacerbations that can require hospitalisation [3]. What would be the risk that a RV vaccine 
might exacerbate airway inflammation in such chronic lung diseases? Since it is known that 
RV infection in asthma induces Th2 responses that are linked to lower airway disease [38] it 
is of concern that a RV vaccine might exacerbate this response, particularly following 
natural RV exposure. Thus, the favoured RV vaccine approach should promote Th1 
responses which is hypothesised to reset the unbalanced immune responses observed in 
asthmatics. Such an approach as outlined above has been demonstrated already in mice [7]. 
Whether the vaccine induced enhancement of Th1 cell responses to RV will prove a safe 
strategy for preventing RV-induced disease awaits confirmation in a clinical trial.
A secondary population that would benefit from a RV vaccine are healthy individuals. Here 
a broadly protective RV vaccine could reduce the burden of the common cold. Clearly any 
population receiving a RV vaccine would require initial safety and efficacy testing in 
healthy individuals with subsequent careful monitoring of airways inflammation following 
both natural and experimental RV exposure. This would be necessary to eliminate the 
possibility of an undesirable disease augmentation occurring following challenge as had 
McLean Page 4
J Vaccines Immun. Author manuscript; available in PMC 2015 January 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
occurred previously when testing a formalin inactivated RSV vaccine in infants during the 
1960s [39].
Conclusion
Attempts to produce a protective vaccine to RV’s have failed due to the large number of 
antigenically distinct serotypes and the lack of a suitable small animal model of infection to 
test candidates in. The recent discovery of a previously unrecognised clade of RV’s has 
complicated this further. Nevertheless, studies in immunised animals have demonstrated that 
significant cross-serotype protection is possible. With the advent of small animal 
immunisation and challenge models, suitable vaccine candidates can now be evaluated 
thoroughly before translation to humans. The quest for a RV vaccine now seems somewhat 
less forlorn than it did a decade ago.
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Figure 1. 
Schematic diagram of RV polyprotein displaying individual proteins as boxes. The 
polyprotein is organised into the N terminal proximal structural proteins (capsid proteins 
VP4, VP2, VP3 and VP1) followed by the non-structural proteins (P2A, P2B, P2C, P3A, 
VPg, P3B, Pol) which are C terminal proximal. Regions with >90% conservation among the 
RV types A and B are denoted with a black line and regions displaying <70% conservation 
are marked with a grey line. The region at the N terminus that corresponds to the VP0 
experimental vaccine is marked with a double line.
McLean Page 8
J Vaccines Immun. Author manuscript; available in PMC 2015 January 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
McLean Page 9
Table 1
Summary of early clinical studies investigating efficacy of RV vaccines.
Vaccine Administration route Findings Reference
Formalin inactivated RV3, RV7, RV10, 
RV13, RV14, RV18, RV22, RV42, 
RV43, RV55 (decavalent)
Intramuscular Minimal homologous and heterologous 
neutralizing antibody responses Hamory 1975 [22]
Formalin inactivated RV13 Subcutaneous
Homotypic neutralising antibody generated 
and reduced viral shedding upon homotypic 
challenge
Douglas 1972 [21]
Formalin inactivated RV13 Intranasal Resistance to homotypic challenge Buscho 1972 [20]
Formalin inactivated RV13 Intranasal Protection to homotypic challenge Perkins 1969 [19]
Formalin inactivated RV13 Intranasal & intramuscular
Protection to homotypic challenge by 
intranasal immunization & correlated with 
level of nasal neutralising antibody
Perkins 1969 [18]
Formalin inactivated single strain Intranasal Protection to homotypic challenge but not heterotypic challenge Mitchison 1965 [17]
Live & formalin inactivated single strain Intranasal & intramuscular
Increased homotypic antibody responses 
with live intranasal and inactive 
intramuscular
Doggett 1963 [16]
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Table 2
Summary of animal studies investigating RV antibodies after vaccination.
Immunogen & Animal model Administration route Findings Reference
Inactivated RV16
Cotton rat Intramuscular
Generation of cross-serotype neutralising antibody 
responses following intranasal challenge Blanco 2014 [37]
Recombinant VP0 of RV16
Mouse Subcutaneous
Generation of cross-serotype neutralising antibody 
responses following intranasal challenge Glanville 2013 [7]
Inactivated RV1B
Mouse Subcutaneous
Generation of cross-serotype neutralising antibody 
responses following intranasal challenge McLean 2012 [23]
Recombinant VP1 of RV89 & RV14
Rabbit & mouse Subcutaneous
Generation of cross-serotype neutralising antibody 
responses Edlmayr 2011 [34]
VP4 peptides of RV14
Rabbit Subcutaneous
Generation of cross-serotype neutralising antibody 
responses Katpally 2009 [33]
VP1 & VP3 peptides of RV14
Rabbit Subcutaneous
Generation of cross-serotype neutralising antibody 
responses McCray 1987 [32]
Numerous RV serotypes individually
Rabbit Intravenous Extensive cross-serotype binding antibody responses Cooney 1975 [30]
J Vaccines Immun. Author manuscript; available in PMC 2015 January 13.
